Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2021

01-12-2021 | Breast Cancer | Review

Invasive lobular carcinoma of the breast: the increasing importance of this special subtype

Authors: Amy E. McCart Reed, Lauren Kalinowski, Peter T. Simpson, Sunil R. Lakhani

Published in: Breast Cancer Research | Issue 1/2021

Login to get access

Abstract

Invasive lobular carcinoma (ILC) is the most common of the breast cancer special types, accounting for up to 15% of all breast cancer cases. ILCs are noted for their lack of E-cadherin function, which underpins their characteristic discohesive growth pattern, with cells arranged in single file and dispersed throughout the stroma. Typically, tumours are luminal in molecular subtype, being oestrogen and progesterone receptor positive, and HER2 negative. Since last reviewing the lobular literature (McCart Reed et al., Breast Cancer Res 17:12, 2015), there has been a considerable increase in research output focused on this tumour type, including studies into the pathology and management of disease, a high-resolution definition of the genomic landscape of tumours as well as the evolution of several potential therapeutic avenues. There abounds a huge amount of new data, which we will review herein.
Literature
1.
Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol. 2005;205(2):248–54.PubMedCrossRef
2.
Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchio C, Reis-Filho JS. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology. 2010;57(2):171–92.PubMedCrossRef
3.
World Health Organisation Classification of Tumours Editorial Board. Breast Tumours, 5th edn. Lyon: International Agency for Research on Cancer (IARC); 2019.
4.
Schnitt SJ, Brogi E, Chen YY, King TA, Lakhani SR. American Registry of Pathology expert opinions: the spectrum of lobular carcinoma in situ: diagnostic features and clinical implications. Ann Diagn Pathol. 2020;45:151481.PubMedPubMedCentralCrossRef
5.
Ginter PS, D'Alfonso TM. Current concepts in diagnosis, molecular features, and management of lobular carcinoma in situ of the breast with a discussion of morphologic variants. Arch Pathol Lab Med. 2017;141(12):1668–78.PubMedCrossRef
6.
McCart Reed AE, Kutasovic JR, Lakhani SR, Simpson PT. Invasive lobular carcinoma of the breast: morphology, biomarkers and ‘omics. Breast Cancer Res. 2015;17:12.PubMedCrossRef
7.
8.
Weidner N, Semple JP. Pleomorphic variant of invasive lobular carcinoma of the breast. Hum Pathol. 1992;23(10):1167–71.PubMedCrossRef
9.
Shousha S, Backhous CM, Alaghband-Zadeh J, Burn I. Alveolar variant of invasive lobular carcinoma of the breast. A tumor rich in estrogen receptors. Am J Clin Pathol. 1986;85(1):1–5.PubMedCrossRef
10.
Fisher ER, Gregorio RM, Redmond C, Fisher B. Tubulolobular invasive breast cancer: a variant of lobular invasive cancer. Hum Pathol. 1977;8(6):679–83.PubMedCrossRef
11.
Fechner RE. Histologic variants of infiltrating lobular carcinoma of the breast. Hum Pathol. 1975;6(3):373–8.PubMedCrossRef
12.
Eusebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum Pathol. 1992;23(6):655–62.PubMedCrossRef
13.
Harris M, Howell A, Chrissohou M, Swindell RI, Hudson M, Sellwood RA. A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer. 1984;50(1):23–30.PubMedPubMedCentralCrossRef
14.
Lamovec J, Bracko M. Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol. 1991;48(1):28–33.PubMedCrossRef
15.
Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6(3):R149–56.PubMedPubMedCentralCrossRef
16.
Mathew A, Rajagopal PS, Villgran V, Sandhu GS, Jankowitz RC, Jacob M, et al. Distinct pattern of metastases in patients with invasive lobular carcinoma of the breast. Geburtshilfe Frauenheilkd. 2017;77(6):660–6.PubMedPubMedCentralCrossRef
17.
Inoue M, Nakagomi H, Nakada H, Furuya K, Ikegame K, Watanabe H, et al. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer. Breast Cancer. 2017;24(5):667–72.PubMedCrossRef
18.
Kutasovic JR, McCart Reed AE, Males R, Sim S, Saunus JM, Dalley A, et al. Breast cancer metastasis to gynaecological organs: a clinico-pathological and molecular profiling study. J Pathol Clin Res. 2019;5(1):25–39.PubMedCrossRef
19.
Tsagkaraki IM, Kourouniotis CD, Gomatou GL, Syrigos NK, Kotteas EA. Orbital metastases of invasive lobular breast carcinoma. Breast Dis. 2019;38(3–4):85–91.PubMedCrossRef
20.
Spraker MB, Francis CE, Korde L, Kim J, Halasz L. Solitary orbital metastasis 35 years after a diagnosis of lobular carcinoma in situ. Cureus. 2017;9(6):e1404.PubMedPubMedCentral
21.
Wolstencroft SJ, Hodder SC, Askill CF, Sugar AW, Jones EW, Griffiths AP. Orbital metastasis due to interval lobular carcinoma of the breast: a potential mimic of lymphoma. Arch Ophthalmol. 1999;117(10):1419–21.PubMedCrossRef
22.
Blohmer M, Zhu L, Atkinson JM, Beriwal S, Rodriguez-Lopez JL, Rosenzweig M, et al. Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology. Breast Cancer Res. 2020;22(1):70.PubMedPubMedCentralCrossRef
23.
Shamir ER, Chen YY, Chu T, Pekmezci M, Rabban JT, Krings G. Pleomorphic and florid lobular carcinoma in situ variants of the breast: a clinicopathologic study of 85 cases with and without invasive carcinoma from a single academic center. Am J Surg Pathol. 2019;43(3):399–408.PubMedCrossRef
24.
Foschini MP, Miglio R, Fiore R, Baldovini C, Castellano I, Callagy G, et al. Pre-operative management of pleomorphic and florid lobular carcinoma in situ of the breast: report of a large multi-institutional series and review of the literature. Eur J Surg Oncol. 2019;45(12):2279–86.PubMedCrossRef
25.
Chen YY, Hwang ES, Roy R, DeVries S, Anderson J, Wa C, et al. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol. 2009;33(11):1683–94.PubMedPubMedCentralCrossRef
26.
Shin SJ, Lal A, De Vries S, Suzuki J, Roy R, Hwang ES, et al. Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ. Hum Pathol. 2013;44(10):1998–2009.PubMedCrossRef
27.
Harrison BT, Nakhlis F, Dillon DA, Soong TR, Garcia EP, Schnitt SJ, et al. Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations. Mod Pathol. 2020;33(7):1287-97.
28.
Sokolova A, Lakhani SR. Lobular carcinoma in situ: diagnostic criteria and molecular correlates. Mod Pathol. 2020.
29.
Lee JY, Schizas M, Geyer FC, Selenica P, Piscuoglio S, Sakr RA, et al. Lobular carcinomas in situ display intralesion genetic heterogeneity and clonal evolution in the progression to invasive lobular carcinoma. Clin Cancer Res. 2019;25(2):674–86.PubMedCrossRef
30.
Begg CB, Ostrovnaya I, Carniello JV, Sakr RA, Giri D, Towers R, et al. Clonal relationships between lobular carcinoma in situ and other breast malignancies. Breast Cancer Res. 2016;18(1):66.PubMedPubMedCentralCrossRef
31.
Lien HC, Chen YL, Juang YL, Jeng YM. Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast. Breast Cancer Res Treat. 2015;150(2):447–55.PubMedCrossRef
32.
Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 2015;163(2):506–19.PubMedPubMedCentralCrossRef
33.
Shamir ER, Chen YY, Krings G. Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma. Mod Pathol. 2020:33(6):1078-91.
34.
Michaut M, Chin SF, Majewski I, Severson TM, Bismeijer T, de Koning L, et al. Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Sci Rep. 2016;6:18517.PubMedPubMedCentralCrossRef
35.
Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, et al. Genomic characterization of primary invasive lobular breast cancer. J Clin Oncol. 2016;34(16):1872–81.PubMedCrossRef
36.
Rosa-Rosa JM, Caniego-Casas T, Leskela S, Cristobal E, Gonzalez-Martinez S, Moreno-Moreno E, et al. High frequency of ERBB2 activating mutations in invasive lobular breast carcinoma with pleomorphic features. Cancers (Basel) 2019;11(1):74.
37.
Zhu S, Ward BM, Yu J, Matthew-Onabanjo AN, Janusis J, Hsieh CC et al: IRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma. JCI Insight 2018;3(8):e97398.
38.
Richard F, Majjaj S, Venet D, Rothe F, Pingitore J, Boeckx B, et al. Characterization of stromal tumor-infiltrating lymphocytes and genomic alterations in metastatic lobular breast cancer. Clin Cancer Res. 2020;26(23):6254-65.
39.
Pareja F, Ferrando L, Lee SSK, Beca F, Selenica P, Brown DN, et al. The genomic landscape of metastatic histologic special types of invasive breast cancer. NPJ Breast Cancer. 2020;6:53.PubMedPubMedCentralCrossRef
40.
Sokol ES, Feng YX, Jin DX, Basudan A, Lee AV, Atkinson JM, et al. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer. Ann Oncol. 2019;30(1):115–23.PubMedCrossRef
41.
Christgen M, Bartels S, Radner M, Raap M, Rieger L, Christgen H, et al. ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling. Genes Chromosomes Cancer. 2019;58(3):175–85.PubMedCrossRef
42.
Cao L, Basudan A, Sikora MJ, Bahreini A, Tasdemir N, Levine KM, et al. Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma. Cancer Lett. 2019;461:21–30.PubMedPubMedCentralCrossRef
43.
Deniziaut G, Tille JC, Bidard FC, Vacher S, Schnitzler A, Chemlali W, et al. ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas. Oncotarget. 2016;7(45):73337–46.PubMedPubMedCentralCrossRef
44.
Ping Z, Siegal GP, Harada S, Eltoum IE, Youssef M, Shen T, et al. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast. Oncotarget. 2016;7(49):80655–63.PubMedPubMedCentralCrossRef
45.
Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, et al. Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplified metastatic breast cancer. Clin Cancer Res. 2017;23(19):5687–95.PubMedPubMedCentralCrossRef
46.
Ross JS, Wang K, Sheehan CE, Boguniewicz AB, Otto G, Downing SR, et al. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res. 2013;19(10):2668–76.PubMedCrossRef
47.
Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer. 2008;44(1):73–83.PubMedCrossRef
48.
Jung SP, Lee SK, Kim S, Choi MY, Bae SY, Kim J, et al. Invasive pleomorphic lobular carcinoma of the breast: clinicopathologic characteristics and prognosis compared with invasive ductal carcinoma. J Breast Cancer. 2012;15(3):313–9.PubMedPubMedCentralCrossRef
49.
Ohashi R, Matsubara M, Watarai Y, Yanagihara K, Yamashita K, Tsuchiya SI, et al. Pleomorphic lobular carcinoma of the breast: a comparison of cytopathological features with other lobular carcinoma variants. Cytopathology. 2017;28(2):122–30.PubMedCrossRef
50.
Rosenthal SI, Depowski PL, Sheehan CE, Ross JS. Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer. Appl Immunohistochem Mol Morphol. 2002;10(1):40–6.PubMed
51.
Lim ST, Yu JH, Park HK, Moon BI, Ko BK, Suh YJ. A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population. World J Surg Oncol. 2014;12:56.PubMedPubMedCentralCrossRef
52.
Flores-Diaz D, Arce C, Flores-Luna L, Reynoso-Noveron N, Lara-Medina F, Matus JA, et al. Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients. Breast Cancer Res Treat. 2019;176(1):243–9.PubMedCrossRef
53.
Altundag K. HER2+ and triple-negative phenotypes in invasive lobular carcinoma might have different specific biological features. Breast Cancer Res Treat. 2019;176(3):719.PubMedCrossRef
54.
Da Ros L, Moretti A, Querzoli P, Pedriali M, Lupini L, Bassi C, et al. HER2-positive lobular versus ductal carcinoma of the breast: pattern of first recurrence and molecular insights. Clin Breast Cancer. 2018;18(5):e1133–9.PubMedCrossRef
55.
Christgen M, Gluz O, Harbeck N, Kates RE, Raap M, Christgen H, et al. Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer. Cancer. 2020;126(22):4847–58.PubMedCrossRef
56.
Viale G, Rotmensz N, Maisonneuve P, Orvieto E, Maiorano E, Galimberti V, et al. Lack of prognostic significance of “classic” lobular breast carcinoma: a matched, single institution series. Breast Cancer Res Treat. 2009;117(1):211–4.PubMedCrossRef
57.
Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber RD, Dowsett M, et al. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. J Clin Oncol. 2013;31(16):1954–60.PubMedCrossRef
58.
McCart Reed AE, Kutasovic JR, Nones K, Saunus JM, Da Silva L, Newell F, et al. Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology. J Pathol. 2018;244(4):460–8.PubMedPubMedCentralCrossRef
59.
Suryadevara A, Paruchuri LP, Banisaeed N, Dunnington G, Rao KA. The clinical behavior of mixed ductal/lobular carcinoma of the breast: a clinicopathologic analysis. World J Surg Oncol. 2010;8:51.PubMedPubMedCentralCrossRef
60.
Arps DP, Healy P, Zhao L, Kleer CG, Pang JC. Invasive ductal carcinoma with lobular features: a comparison study to invasive ductal and invasive lobular carcinomas of the breast. Breast Cancer Res Treat. 2013;138(3):719–26.PubMedPubMedCentralCrossRef
61.
Zengel B, Yararbas U, Duran A, Uslu A, Eliyatkin N, Demirkiran MA, et al. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast. Breast Cancer. 2015;22(4):374–81.PubMedCrossRef
62.
Rakha EA, Gill MS, El-Sayed ME, Khan MM, Hodi Z, Blamey RW, et al. The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology. Breast Cancer Res Treat. 2009;114(2):243–50.PubMedCrossRef
63.
Metzger-Filho O, Ferreira AR, Jeselsohn R, Barry WT, Dillon DA, Brock JE, et al. Mixed invasive ductal and lobular carcinoma of the breast: prognosis and the importance of histologic grade. Oncologist. 2019;24(7):e441–9.PubMedCrossRef
64.
Bharat A, Gao F, Margenthaler JA. Tumor characteristics and patient outcomes are similar between invasive lobular and mixed invasive ductal/lobular breast cancers but differ from pure invasive ductal breast cancers. Am J Surg. 2009;198(4):516–9.PubMedCrossRef
65.
Christgen M, Bartels S, van Luttikhuizen JL, Bublitz J, Rieger LU, Christgen H, et al. E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements. Mod Pathol. 2020;33(12):2483-98.
66.
Motanagh SA, Muller KE. Invasive lobular carcinoma with papillary features: a newly described variant that poses a difficult histologic differential diagnosis. Breast J. 2020;26(6):1231-3.
67.
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259–71.CrossRefPubMed
68.
Desmedt C, Salgado R, Fornili M, Pruneri G, Van den Eynden G, Zoppoli G, et al. Immune infiltration in invasive lobular breast cancer. J Natl Cancer Inst. 2018;110(7):768–76.PubMedPubMedCentralCrossRef
69.
Tille JC, Vieira AF, Saint-Martin C, Djerroudi L, Furhmann L, Bidard FC, et al. Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. Mod Pathol. 2020;33(11):2198-07. .
70.
Du T, Zhu L, Levine KM, Tasdemir N, Lee AV, Vignali DAA, et al. Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. Sci Rep. 2018;8(1):7205.PubMedPubMedCentralCrossRef
71.
Sobral-Leite M, Salomon I, Opdam M, Kruger DT, Beelen KJ, van der Noort V, et al. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. Breast Cancer Res. 2019;21(1):90.PubMedPubMedCentralCrossRef
72.
Oesterreich S, Lucas PC, McAuliffe PF, Bruno TC, Vignali DAA. Opening the door for immune oncology studies in invasive lobular breast cancer. J Natl Cancer Inst. 2018;110(7):696–8.PubMedCrossRef
73.
Simpson PT, Reis-Filho JS, Lambros MB, Jones C, Steele D, Mackay A, et al. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol. 2008;215(3):231–44.PubMedCrossRef
74.
Orvieto E, Maiorano E, Bottiglieri L, Maisonneuve P, Rotmensz N, Galimberti V, et al. Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer. 2008;113(7):1511–20.PubMedCrossRef
75.
76.
Desmedt C, Pingitore J, Rothe F, Marchio C, Clatot F, Rouas G, et al. ESR1 mutations in metastatic lobular breast cancer patients. NPJ Breast Cancer. 2019;5:9.PubMedPubMedCentralCrossRef
77.
Basudan A, Priedigkeit N, Hartmaier RJ, Sokol ES, Bahreini A, Watters RJ, et al. Frequent ESR1 and CDK pathway copy-number alterations in metastatic breast cancer. Mol Cancer Res. 2019;17(2):457–68.CrossRefPubMed
78.
Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34(3):427–38 e426.PubMedPubMedCentralCrossRef
79.
Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, et al. Acquired HER2 mutations in ER(+) metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nat Genet. 2019;51(2):207–16.CrossRefPubMed
80.
Kurozumi S, Alsaleem M, Monteiro CJ, Bhardwaj K, Joosten SEP, Fujii T, et al. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. Breast Cancer Res. 2020;22(1):85.PubMedPubMedCentralCrossRef
81.
Bidard FC, Ng CK, Cottu P, Piscuoglio S, Escalup L, Sakr RA, et al. Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. Ann Oncol. 2015;26(8):1704–9.PubMedCrossRef
82.
Kancha RK, von Bubnoff N, Bartosch N, Peschel C, Engh RA, Duyster J. Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. Plos One. 2011;6(10):e26760.PubMedPubMedCentralCrossRef
83.
Carbognin L, Simbolo M, Calio A, Vicentini C, Delfino P, Sperduti I, et al. Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. Breast. 2020;50:56–63.PubMedPubMedCentralCrossRef
84.
De Mattos-Arruda L, Sammut SJ, Ross EM, Bashford-Rogers R, Greenstein E, Markus H, et al. The genomic and immune landscapes of lethal metastatic breast cancer. Cell Rep. 2019;27(9):2690–708 e2610.PubMedPubMedCentralCrossRef
85.
Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, Martincorena I, et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell. 2017;32(2):169–84 e167.PubMedPubMedCentralCrossRef
86.
Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22(3):207–19.PubMedCrossRef
87.
Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29(32):4273–8.PubMedCrossRef
88.
Lal S, McCart Reed AE, de Luca XM, Simpson PT. Molecular signatures in breast cancer. Methods. 2017;131:135–46.PubMedCrossRef
89.
Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, et al. Genomic grade adds prognostic value in invasive lobular carcinoma. Ann Oncol. 2013;24(2):377–84.PubMedCrossRef
90.
Beumer IJ, Persoon M, Witteveen A, Dreezen C, Chin SF, Sammut SJ, et al. Prognostic value of MammaPrint((R)) in invasive lobular breast cancer. Biomark Insights. 2016;11:139–46.PubMedPubMedCentralCrossRef
91.
Metzger O, Cardoso F, Poncet C, Desmedt C, Linn S, Wesseling J, et al. Clinical utility of MammaPrint testing in invasive lobular carcinoma: results from the MINDACT phase III trial. Eur J Cancer. 2020;138:S5–6.CrossRef
92.
Bomeisl PE, Thompson CL, Harris LN, Gilmore HL. Comparison of Oncotype DX recurrence score by histologic types of breast carcinoma. Arch Pathol Lab Med. 2015;139(12):1546–9.PubMedCrossRef
93.
Wilson PC, Chagpar AB, Cicek AF, Bossuyt V, Buza N, Mougalian S, et al. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score. Breast J. 2018;24(6):976–80.PubMedCrossRef
94.
Felts JL, Zhu J, Han B, Smith SJ, Truica CI. An analysis of Oncotype DX recurrence scores and clinicopathologic characteristics in invasive lobular breast cancer. Breast J. 2017;23(6):677–86.PubMedCrossRef
95.
Hanna MG, Bleiweiss IJ, Nayak A, Jaffer S. Correlation of Oncotype DX recurrence score with histomorphology and immunohistochemistry in over 500 patients. Int J Breast Cancer. 2017;2017:1257078.PubMedPubMedCentralCrossRef
96.
Wang J, He ZY, Dong Y, Sun JY, Zhang WW, Wu SG. The distribution and outcomes of the 21-gene recurrence score in T1-T2N0 estrogen receptor-positive breast cancer with different histologic subtypes. Front Genet. 2018;9:638.PubMedPubMedCentralCrossRef
97.
Kizy S, Huang JL, Marmor S, Tuttle TM, Hui JYC. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast. Breast Cancer Res Treat. 2017;165(3):757–63.PubMedCrossRef
98.
99.
Laenkholm AV, Jensen MB, Eriksen JO, Roslind A, Buckingham W, Ferree S, et al. Population-based study of Prosigna-PAM50 and outcome among postmenopausal women with estrogen receptor-positive and HER2-negative operable invasive lobular or ductal breast cancer. Clin Breast Cancer. 2020;20(4):e423-32.
100.
Sestak I, Filipits M, Buus R, Rudas M, Balic M, Knauer M, et al. Prognostic value of EndoPredict in women with hormone receptor positive, HER2-negative invasive lobular breast cancer. Clin Cancer Res. 2020;26(17):4682-7.
101.
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–21.PubMedPubMedCentralCrossRef
102.
Tsai ML, Lillemoe TJ, Finkelstein MJ, Money JE, Susnik B, Grimm E, et al. Utility of Oncotype DX risk assessment in patients with invasive lobular carcinoma. Clin Breast Cancer. 2016;16(1):45–50.PubMedCrossRef
103.
Conlon N, Ross DS, Howard J, Catalano JP, Dickler MN, Tan LK. Is there a role for Oncotype Dx testing in invasive lobular carcinoma? Breast J. 2015;21(5):514–9.PubMedPubMedCentralCrossRef
104.
McVeigh TP, Kerin MJ. Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer. Breast Cancer (Dove Med Press). 2017;9:393–400.
105.
Wu SG, Zhang WW, Wang J, Lian CL, Sun JY, Chen YX, et al. Progesterone receptor status and tumor grade predict the 21-gene recurrence score of invasive lobular breast cancer. Biomark Med. 2019;13(12):1005–12.PubMedCrossRef
106.
Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genet. 2015;8:54.
107.
Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17(18):6012–20.PubMedCrossRef
108.
McCart Reed AE, Lal S, Kutasovic JR, Wockner L, Robertson A, de Luca XM, et al. LobSig is a multigene predictor of outcome in invasive lobular carcinoma. NPJ Breast Cancer. 2019;5:18.PubMedPubMedCentralCrossRef
109.
Tasdemir N, Bossart EA, Li Z, Zhu L, Sikora MJ, Levine KM, et al. Comprehensive phenotypic characterization of human invasive lobular carcinoma cell lines in 2D and 3D cultures. Cancer Res. 2018;78(21):6209–22.PubMedPubMedCentralCrossRef
110.
Martin LA, Ribas R, Simigdala N, Schuster E, Pancholi S, Tenev T, et al. Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nat Commun. 2017;8(1):1865.PubMedPubMedCentralCrossRef
111.
Stires H, Heckler MM, Fu X, Li Z, Grasso CS, Quist MJ, et al. Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities. Mol Cell Endocrinol. 2018;471:105–17.PubMedCrossRef
112.
Sikora MJ, Jacobsen BM, Levine K, Chen J, Davidson NE, Lee AV, et al. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. Breast Cancer Res. 2016;18(1):92.PubMedPubMedCentralCrossRef
113.
Shackleford MT, Rao DM, Bordeaux EK, Hicks HM, Towers CG, Sottnik JL, et al. Estrogen regulation of mTOR signaling and mitochondrial function in invasive lobular carcinoma cell lines requires WNT4. Cancers (Basel) 2020;12(10):2931.
114.
Harrell JC, Shroka TM, Jacobsen BM. Estrogen induces c-Kit and an aggressive phenotype in a model of invasive lobular breast cancer. Oncogenesis. 2017;6(11):396.PubMedPubMedCentralCrossRef
115.
Tasdemir N, Ding K, Savariau L, Levine KM, Du T, Elangovan A, et al. Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma. Sci Rep. 2020;10(1):11487.PubMedPubMedCentralCrossRef
116.
Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res. 2006;12(22):6652–62.PubMedCrossRef
117.
Levine KM, Priedigkeit N, Basudan A, Tasdemir N, Sikora MJ, Sokol ES, et al. FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype. NPJ Breast Cancer. 2019;5:19.PubMedPubMedCentralCrossRef
118.
Kas SM, de Ruiter JR, Schipper K, Annunziato S, Schut E, Klarenbeek S, et al. Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma. Nat Genet. 2017;49(8):1219–30.PubMedCrossRef
119.
Kas SM, de Ruiter JR, Schipper K, Schut E, Bombardelli L, Wientjens E, et al. Transcriptomics and transposon mutagenesis identify multiple mechanisms of resistance to the FGFR inhibitor AZD4547. Cancer Res. 2018;78(19):5668–79.PubMedCrossRef
120.
Nagle AM, Levine KM, Tasdemir N, Scott JA, Burlbaugh K, Kehm J, et al. Loss of E-cadherin enhances IGF1-IGF1R pathway activation and sensitizes breast cancers to anti-IGF1R/InsR inhibitors. Clin Cancer Res. 2018;24(20):5165–77.PubMedPubMedCentralCrossRef
121.
Klarenbeek S, Doornebal CW, Kas SM, Bonzanni N, Bhin J, Braumuller TM, et al. Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system. Oncoimmunology. 2020;9(1):1724049.PubMedPubMedCentralCrossRef
122.
Schipper K, Drenth AP, van der Burg E, Cornelissen S, Klarenbeek S, Nethe M, et al. Truncated ASPP2 drives initiation and progression of invasive lobular carcinoma via distinct mechanisms. Cancer Res. 2020;80(7):1486–97.PubMedCrossRefPubMedCentral
123.
Du T, Sikora MJ, Levine KM, Tasdemir N, Riggins RB, Wendell SG, et al. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer. Breast Cancer Res. 2018;20(1):106.PubMedPubMedCentralCrossRef
124.
Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, et al. E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer. Cancer Discov. 2018;8(4):498–515.PubMedPubMedCentralCrossRef
125.
Teo K, Gomez-Cuadrado L, Tenhagen M, Byron A, Ratze M, van Amersfoort M, et al. E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer. Sci Rep. 2018;8(1):15454.PubMedPubMedCentralCrossRef
126.
Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, et al. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer Res. 2014;74(5):1463–74.PubMedPubMedCentralCrossRef
127.
Sreekumar S, Levine KM, Sikora MJ, Chen J, Tasdemir N, Carter D, et al. Differential regulation and targeting of estrogen receptor alpha turnover in invasive lobular breast carcinoma. Endocrinology 2020;161(9):bqaa109.
128.
129.
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–36.PubMedCrossRef
130.
131.
132.
133.
134.
Perez-Garcia J, Cortes J, Metzger Filho O. Efficacy of single-agent chemotherapy for patients with advanced invasive lobular carcinoma: a pooled analysis from three clinical trials. Oncologist. 2019;24(8):1041–7.PubMedCrossRef
135.
Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, et al. Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1-98 trial. J Clin Oncol. 2019;37(2):105–14.PubMedCrossRef
Metadata
Title
Invasive lobular carcinoma of the breast: the increasing importance of this special subtype
Authors
Amy E. McCart Reed
Lauren Kalinowski
Peter T. Simpson
Sunil R. Lakhani
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2021
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-020-01384-6

Other articles of this Issue 1/2021

Breast Cancer Research 1/2021 Go to the issue

Research article

AKT-mediated phosphorylation of Sox9 induces Sox10 transcription in a murine model of HER2-positive breast cancer

Research article

Long noncoding RNA PVT1 promotes breast cancer proliferation and metastasis by binding miR-128-3p and UPF1

Research article

Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy

Research article

Associations of reproductive breast cancer risk factors with breast tissue composition

Research article

Transcriptome analysis of heterogeneity in mouse model of metastatic breast cancer

Research article

Adolescent and early adulthood inflammation-associated dietary patterns in relation to premenopausal mammographic density
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits